About this trial
This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however this regimen results in higher rates of TRM than other forms of treatment. In recent years, less intense conditioning regimens with radiation and chemotherapy prior to HSCT have been developed. Radiation therapy uses high energy sources to kill cancer cells and shrink tumors while chemotherapy drugs like fludarabine and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This study evaluates whether a two-step approach with lower-intensity regimens of these treatments prior to HSCT reduces the rate of TRM.
Eligibility criteria
Qualifiers
Acute myeloid leukemia
Acute lymphoid leukemia in remission
Myelodysplasia (MDS)
Chronic lymphocytic leukemia (CLL) with no or minimal lymph node involvement
Disqualifiers
None
Trial design
Treatments tested in this trial
- Fludarabine
- Total-Body Irradiation
- Donor Lymphocyte Infusion
- Cyclophosphamide
- Tacrolimus
- Mycophenolate Mofetil
- Hematopoietic Cell Transplantation
- Melphalan
- Bone Marrow Aspiration and Biopsy
- Diagnostic Imaging
- Biospecimen Collection
Treatment groups
Locations
1Map coordinates are unavailable for these locations. Locations are shown below instead.